Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incidental Carcinomas in Prophylactic Specimens in BRCA1 BRCA2 Report of 6 Cases and Review of the Literature

Incidental Carcinomas in Prophylactic Specimens in BRCA1 BRCA2 Report of 6 Cases and Review of... ORIGINAL ARTICLE Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions Report of 6 Cases and Review of the Literature Maria L. Carcangiu, MD,* Bernard Peissel, MD,w Barbara Pasini, MD,z Gianbattista Spatti, MD,y Paolo Radice, PhD,J and Siranoush Manoukian, MDw indicate that small size of the tumors should not preclude Abstract: The identification of germ-line mutations in 2 genes therapy. (BRCA1 and BRCA2) responsible for the majority of hereditary Key Words: BRCA mutations, prophylactic oophorectomy, ovarian cancers has led an increasing number of women carriers gynecologic incidental carcinoma of these mutations to undergo prophylactic oophorectomy (PO) to reduce their risk of subsequent ovarian carcinoma. A large (Am J Surg Pathol 2006;30:1222–1230) number of unexpected, clinically occult neoplasms are thus being discovered. Up to December 2004, the Medical Genetics nactivating mutations of the BRCA1 and BRCA2 genes, Service of the National Cancer Institute in Milan, Italy, has Iwhich encode proteins involved in the control of genome tested 756 probands from breast and/or ovarian cancer families integrity and of cell growth and differentiation, are known for BRCA1 and BRCA2 germ-line mutations. Molecular to increase the susceptibility to breast and ovarian cancer, screening http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Surgical Pathology Wolters Kluwer Health

Incidental Carcinomas in Prophylactic Specimens in BRCA1 BRCA2 Report of 6 Cases and Review of the Literature

Loading next page...
 
/lp/wolters-kluwer-health/incidental-carcinomas-in-prophylactic-specimens-in-brca1-brca2-report-H6sUZRCQ0g

References (39)

ISSN
0147-5185
eISSN
1532-0979
DOI
10.1097/01.pas.0000202161.80739.ac
pmid
17001151
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions Report of 6 Cases and Review of the Literature Maria L. Carcangiu, MD,* Bernard Peissel, MD,w Barbara Pasini, MD,z Gianbattista Spatti, MD,y Paolo Radice, PhD,J and Siranoush Manoukian, MDw indicate that small size of the tumors should not preclude Abstract: The identification of germ-line mutations in 2 genes therapy. (BRCA1 and BRCA2) responsible for the majority of hereditary Key Words: BRCA mutations, prophylactic oophorectomy, ovarian cancers has led an increasing number of women carriers gynecologic incidental carcinoma of these mutations to undergo prophylactic oophorectomy (PO) to reduce their risk of subsequent ovarian carcinoma. A large (Am J Surg Pathol 2006;30:1222–1230) number of unexpected, clinically occult neoplasms are thus being discovered. Up to December 2004, the Medical Genetics nactivating mutations of the BRCA1 and BRCA2 genes, Service of the National Cancer Institute in Milan, Italy, has Iwhich encode proteins involved in the control of genome tested 756 probands from breast and/or ovarian cancer families integrity and of cell growth and differentiation, are known for BRCA1 and BRCA2 germ-line mutations. Molecular to increase the susceptibility to breast and ovarian cancer, screening

Journal

American Journal of Surgical PathologyWolters Kluwer Health

Published: Oct 1, 2006

There are no references for this article.